Infliximab, popularly known as Remicade, is a prescription #Medication used to treat moderate to severe Crohn's Disease. You can see it here in #VirtualReality using Nanome's software. You simply open up a @rcsbPDB file in the software and explore.pic.twitter.com/ICrAUTAa6L
#Rivaroxaban (BAY 59-7939) is an oral Factor Xa inhibitor in clinical development. It is designed to treat thromboembolic disorders. Here you can see it displayed using the Nanome software in #virtualreality. Simply load in the @rcsbPDB file and explore.pic.twitter.com/bmQkvJ4MAw
“I think the biggest innovations of the 21st century will be at the intersection of #biology and #technology. A new era is beginning.” — Steve Jobs...Check out our blog on biopharma: https://blog.matryx.ai/biopharmaceuticals-biotech-the-market-for-new-medical-innovation-1b0670d36a01 …
“Moving forward, a lot of the VR haters that complain about resolution, ergonomics and minor details will disappear,” wrote Nanome CEO @StevenMcCloskey. “We will see a lot less negativity in the VR industry.” https://blog.matryx.ai/virtual-reality-past-present-future-e0995ce386bf …
#ThrowbackThursday - Until now, pharmaceutical companies have had to spend hundreds of millions of dollars a year on third-party timestamp services to document the discovery process of new potential medicines for FDA auditors and to protect their IP. http://bit.ly/MatryxMainnet
Adalimumab, commonly known under the brand name #Humira by @abbvie, treats rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis. Check it out in #VR:pic.twitter.com/4ASkHcQ3jb
Matryx (MTX) News
Matryx (MTX) is currently the #1129 cryptocurrency by market cap at $419.3k USD. Trading volume for Matryx over the last 24 hours is $136.5k USD. There have been no news stories on Matryx over the last 7 days. The most common news source covering Matryx is Matryx Twitter and the most common news category is Project Announcements.